C5aR-Antagonist Significantly Reduces the Deleterious Effect of a Blunt Chest Trauma on Fracture Healing

Stefan Recknagel,1 Ronny Bindl,1 Julian Kurz,1 Tim Wehner,1 Philipp Schoengraf,1 Christian Ehrnthaller,2 Hongchang Qu,3 Florian Gebhard,2 Markus Huber-Lang,2 John D. Lambris,3 Lutz Claes,1 Anita Ignatius1

1Institute of Orthopaedic Research and Biomechanics, Center of Musculoskeletal Research, University of Ulm, Helmholtzstr.14, 89081 Ulm, Germany, 2Department of Traumatology, Hand-, Plastic-, and Reconstructive Surgery, Center of Surgery, Center of Musculoskeletal Research, University of Ulm, Ulm, Germany, 3Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania

Received 10 March 2010; accepted 30 August 2011
Published online 15 September 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jor.21561

ABSTRACT: Confirming clinical evidence, we recently demonstrated that a blunt chest trauma considerably impaired fracture healing in rats, possibly via the interaction of posttraumatic systemic inflammation with local healing processes, the underlying mechanisms being unknown. An important trigger of systemic inflammation is the complement system, with the potent anaphylatoxin C5a. Therefore, we investigated whether the impairment of fracture healing by a severe trauma resulted from systemically activated complement. Rats received a blunt chest trauma and a femur osteotomy stabilized with an external fixator. To inhibit the C5a-dependent posttraumatic systemic inflammation, half of the rats received a C5aR-antagonist intravenously immediately and 12 h after the thoracic trauma. Compared to the controls (control peptide), the treatment with the C5aR-antagonist led to a significantly increased flexural rigidity (three-point-bending test), an improved bony bridging of the fracture gap, and a slightly larger and qualitatively improved callus (μCT, histomorphometry) after 35 days. In conclusion, immunomodulation by a C5aR-antagonist could abolish the deleterious effects of a thoracic trauma on fracture healing, possibly by influencing the function of inflammatory and bone cells locally at the fracture site. C5a could possibly represent a target to prevent delayed bone healing in patients with severe trauma. © 2011 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:581–586, 2012

Keywords: fracture healing; blunt chest trauma; complement

A severe trauma such as a blunt chest trauma is considered a potent initiator of a systemic inflammatory response, being characterized by a strong systemic activation of the complement and coagulation cascades, and the release of pro-inflammatory cytokines and prostanoids.1–3 It was reported that fracture healing was delayed and more non-unions occurred in severely injured patients.4,5 In confirming the clinical evidence, we recently demonstrated experimentally in rats that a blunt chest trauma, which induced a posttraumatic systemic inflammation, considerably impaired fracture healing. This suggests that the systemic inflammatory response disturbs the local inflammatory and regeneration processes in bone, the underlying mechanisms, however, remaining unknown.6

A powerful trigger of the posttraumatic systemic inflammation is the complement system.1,7,8 The complement cascade, consisting of over 30 proteins, is an important component of the innate immunity and can be activated by four pathways, the classical, the lectin, the alternative, and the extrinsic pathways. In all cases the activation pathways lead to the production of the important anaphylatoxin C5a.9,10 In trauma victims, systemic C5a immediately increased within minutes and was strongly correlated with injury severity.11,12 C5a induces for example the migration of phagocytes, degranulation of mast cells, systemic cytokine release, respiratory burst induction, and the regulation of apoptosis in inflammatory cells, thus acting at the very first line of defense in the posttraumatic systemic inflammatory response.1 The excessive activation of complement, however, can also cause harmful effects, for example, immunoparalysis and organ dysfunction.12,13 Due to its strong pro-inflammatory character, C5a is regarded as being the most hazardous molecule in the over-activated complement cascade.1,13,14 Therefore, the question arises as to whether the posttraumatic systemic activation of C5a contributes to delayed fracture healing observed clinically4,5 and experimentally6 after severe injury.

This assumption is also strengthened by a recent study by our group demonstrating for the first time that the cellular receptor for C5a, C5aR, was locally expressed in a distinct spatial and temporal pattern in the fracture callus of rats not only by inflammatory cells but also by osteoblasts, chondroblasts, and osteoclasts in zones of intramembranous and enchondral bone formation.15 Furthermore, in vitro studies revealed that in osteoblasts C5aR activation could induce cell migration15 and cytokine release,16 and also modulate osteoclast formation.17 This suggests that the anaphylatoxin C5a could potentially influence the fine local inflammatory balance of the bone healing process by acting on inflammatory cells as well as on osteoblasts and osteoclasts.

Therefore, in this study we addressed the question, whether the impairment of fracture healing by a severe trauma resulted from systemically activated complement. Based on our previous work6 we hypothesized that the systemic administration of a C5aR-antagonist would at least partly abolish the deleterious effect of a
blunt chest trauma on bone healing in a rat model. The C5aR-antagonist was applied after the thoracic trauma to prevent the immediate C5a-dependent systemic inflammation. The fracture healing outcome was investigated after 35 days.

METHODS

Animal Experiment
The animal experiment was performed according to international regulations for the care and use of laboratory animals, and approved by the local ethical committee (Regierungspra¨sidium Tübingen, Germany). Sixteen male Wistar rats (weight 400–450 g; age 10–12 weeks) received a blunt chest trauma combined with a femur osteotomy that was stabilized with an external fixator. Then the animals received either a C5aR-antagonist (n = 8) or a control peptide (control group, n = 8).

Surgery and Blunt Chest Trauma
Surgery was performed as described previously.6,18 Briefly, a standardized osteotomy gap of 1 mm was created at the mid-shaft of the right femur and fixated with a custom-made external fixator. The offset of the fixator block was 6 mm, resulting in an axial stiffness of 119 N/mm.8 Immediately after surgery the rats received an additional blunt chest trauma under general anesthesia using a blast wave generator as previously described in detail.1,19 This model allows a bilateral, isolated lung contusion by the application of a standardized single blast wave centered on the middle of the thorax and induces a reproducible transient systemic inflammation.1,6 An analgesic (20 mg/kg, Tramal®), Gruenenthall GmbH, Aachen, Germany) was administered subcutaneously during the operation and was diluted in the drinking water (25 mg/L) for the first 3 days following surgery. Each animal was individually housed, given unrestricted access to food and monitored daily for infection and mobility.

C5aR-Antagonist
Immediately after the blunt chest trauma, one group received a C5aR-antagonist (Ac-F[OPdChaWR]; PMX-53) at a dosage of 1 mg/kg intravenously into the penis vein.20,21 The injection was repeated 12 h after the trauma to prevent the immediate C5a-dependent systemic inflammation.1,6 An analgesic (20 mg/kg, Tramal®), Gruenenthall GmbH, Aachen, Germany) was administered subcutaneously during the operation and was diluted in the drinking water (25 mg/L) for the first 3 days following surgery. Each animal was individually housed, given unrestricted access to food and monitored daily for infection and mobility.

Biomechanical Testing
After 35 days the rats were sacrificed and the operated as well as the contralateral intact femora were explanted. Biomechanical testing was performed using a non-destructive, three-point bending test, as described previously.9 Briefly, after removing the fixators, the distal end of each bone was potted in a cylinder using polymethylmethacrylate (Technovit® 3040, Heraeus Kulzer GmbH, Wertheim, Germany) and fixed in a hinge joint whereas the proximal end of the femur rested on the bending support. A quasistatic load was applied in a three-point bending mode with a materials testing machine (1454, Zwick GmbH, Ulm, Germany) using a 500 N load cell (A.S.T. Angewandte System-Technik GmbH, Dresden, Germany) and the flexural rigidity (EI) was calculated from the slope of the force deflection curve. The absolute values of the operated femora were related to the contralateral values of the un-operated femora to eliminate individual differences.

Micro-Computed Tomography
The femora were scanned using a µCT scanning device (Skyscan 1172), operating at a peak voltage of 50 kV and 200 µA at a resolution of 15 µm. The mineralized callus within the former osteotomy gap was segmented and the total tissue volume and the bone volume fraction (BV/TV) were calculated by global thresholding to distinguish between mineralized and non-mineralized tissue.22 The maximum moment of inertia was calculated based on the tissue area on the transversal slices in the fracture gap. The apparent modulus of elasticity was calculated as the flexural rigidity divided by the maximum moment of inertia.24 According to the standard clinical evaluation of X-rays the number of bridged cortices per callus were evaluated in two planes at right angles to one another by using an CT analyzing software (Data viewer, Skyscan, Kontich, Belgium).25 The distal pin hole served as orientation for the exact positioning of the specimens. At least three bridged cortices per callus were considered as a “healed fracture.” Two observers evaluated the cortical bridging independently in a blinded fashion.

Histomorphometry
After fixating the femora in buffered 4% formaldehyde they were dehydrated with ethanol (40–100%) and embedded in methyl methacrylate (Merck KGaA, Darmstadt, Germany). Seventy micrometers longitudinal sections were prepared, which were cut in anterior–posterior direction of the right femur. The pin holes guaranteed the standardized orientation of the sections. Then the sections were stained with Paragon (Toluidin blue and Fuchsin; both Waldeck GmbH & Co KG, Münster, Germany), which stains fibrous tissue in blue, cartilage tissue in purple and mineralized matrix in white-yellow. In the former osteotomy gap the newly formed tissue was evaluated by using a light microscope (Leica DMi6000B) at a fivefold magnification. The amount of bone, cartilage and fibrous tissue was assessed by circumscribing the corresponding areas with image analysis software (Leica MMAP 1.4.0 Imaging System, Leica, Heerbrugg, Switzerland powered by MetaMorph®).

Statistical Analysis
Results are presented as medians and interquartile ranges (IR). For statistical analysis, the software PASW Statistics 18.0 (SPSS, Inc., Chicago, IL) was used. Differences between groups regarding flexural rigidity, µCT-parameters, and histomorphometrical data were calculated using a Mann–Whitney U-test, whereas differences between groups regarding the number of bridged cortices were calculated using the Fisher exact test. The level of significance was p < 0.05.

RESULTS

Biomechanical Testing
The treatment of the animals with the C5aR-antagonist after blunt chest trauma significantly increased the flexural rigidity (Ctrl: EI = 46.54% (IR: 27.44); C5aR-Ag: EI = 72.18% (IR: 66.50)) of the callus by about 55% compared to the control group, which received the control peptide (Fig. 1).
Micro-Computed Tomography
The application of the C5aR-antagonist led to a tendency for higher total callus volume, maximum moment of inertia, and apparent modulus of elasticity. None of the parameters showed statistical significance compared to the control group (Table 1). The results might indicate a somewhat larger and qualitatively superior callus in the rats treated with the C5aR-antagonist. Furthermore, the fracture callus of rats which received the C5aR-antagonist showed considerably more bridged cortices compared to the control group, even though this was not statistically significant (Table 2).

Histomorphometry
The histomorphometrical results confirmed the results of the μCT analysis showing a slightly increased callus with more bone in the C5aR-antagonist treated group (Fig. 2).

DISCUSSION
This study demonstrated that systemically activated complement significantly contributes to the impairment of bone healing observed after severe trauma. Our results revealed that the application of a C5aR-antagonist during the initial phase of the posttraumatic inflammatory response abolished the deleterious effect of a blunt chest trauma on fracture healing in a rat model. This was reflected by a considerably improved flexural rigidity of the fracture callus, a higher bony bridging between the fracture fragments and a slightly larger and qualitatively improved callus formation in the rats treated with the C5aR-antagonist.

In a previous study we showed that a blunt chest trauma significantly impaired fracture healing in the same rat model. The flexural rigidity of the healed femora was reduced by approximately 60% and a smaller callus with an inferior quality was formed compared to the control group, which did not receive a thoracic trauma. We proposed that the complex systemic inflammatory response induced by the thoracic trauma disturbed fracture healing locally, the underlying mechanisms remaining unknown. The rat blunt chest trauma model used in the present study is well-established and induces a reproducible and transient systemic inflammatory response. Reflecting clinical data in polytraumatic patients, Flierl et al. recently showed that the complement system, especially C5a, triggered the complex systemic inflammatory response in this experimental model by enhancing the systemic cytokine release as well as disturbing the neutrophil function. Neutrophils displayed an enhanced chemoattractant activity, phagocytosis, and production of reactive oxygen species followed by prolonged functional defects. Furthermore, the systemic administration of an anti-C5a antibody immediately after the blunt chest trauma decreased the systemic cytokine release as well as the number of circulating neutrophils, and enhanced neutrophil function. This suggests that antagonizing excessive C5a might improve the outcome of a blunt chest trauma. To investigate whether the systemic C5a increase is also responsible for the deleterious effects of the blunt chest trauma on bone healing we applied a specific C5aR-antagonist. Blocking of C5aR completely abolished the negative impact of the thoracic trauma on fracture healing, suggesting that C5a was one of the main players in this scenario. The flexural rigidity of the callus increased significantly in the C5aR-antagonist treated group and nearly reached the levels of the intact contralateral femur. The biomechanical results correlated with an improved bony bridging of the fracture gap. Furthermore, the callus of the C5aR-antagonist treated group and the apparent modulus of elasticity, describing the mechanical quality of the newly formed callus, were slightly increased. Histomorphometry also indicated a slightly increased amount of newly formed bone in the

Table 1. μ-Computed Tomography Analysis of the Calli of Rats without (Control) or with Treatment with a C5aR-Antagonist after Blunt Chest Trauma

<table>
<thead>
<tr>
<th>Measure</th>
<th>Control</th>
<th>C5aR-Antagonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total callus volume (mm³)</td>
<td>15.72 (IR: 6.35)</td>
<td>16.47 (IR: 7.75)</td>
</tr>
<tr>
<td>BV/TV (%)</td>
<td>85.55 (IR: 11.15)</td>
<td>82.26 (IR: 21.89)</td>
</tr>
<tr>
<td>Maximum moment of inertia (mm⁴)</td>
<td>33.32 (IR: 26.60)</td>
<td>41.12 (IR: 36.93)</td>
</tr>
<tr>
<td>Apparent modulus of elasticity (MPa)</td>
<td>2469.98 (IR: 5357.93)</td>
<td>6214.25 (IR: 6470.93)</td>
</tr>
</tbody>
</table>
C5aR-antagonist treated group. The radiological and histological results revealed that the predominant tissue in the fracture callus in both groups was newly formed bone, indicating that the healing process had widely progressed after a period of 35 days. Nevertheless, the differences between the C5aR-antagonist treated and the control group in the biomechanical outcome were still considerable. In ongoing studies earlier investigation time points are included to evaluate differences in callus composition during the course of healing.

At present little is known about the role of C5a in fracture healing. It is well known that complement is locally activated after tissue injury, and is important for an adequate and effective inflammation, for example, by increasing vascular permeability, recruitment of leukocytes, lymphocyte activation, opsonization of pathogens, and clearance of necrotic and apoptotic tissues at the site of injury.27,28 Local activation of complement might, therefore, play an essential role in bone regeneration, especially in the fracture hematoma and the early stages of bone healing where inflammatory cells are predominant.29,30 This was confirmed by a recent study of our group demonstrating that C5aR was abundantly expressed by these cells, but intriguingly also by osteoblasts, chondroblasts, and osteoclasts in zones of intramembranous and enchondral ossification.15 This suggests that C5a may be essential for regular regeneration processes during all stages of fracture healing.

After a blunt chest trauma systemic C5a is increased very rapidly and transiently.1 Accordingly, we applied the C5aR-antagonist during the first hours after the blunt chest trauma and were able to significantly improve the fracture healing outcome after 35 days, indicating that C5a triggers determining effects in the very early healing phase. Systemically generated C5a causes a cascade of events, which could interact in several ways with the local fine-tuned inflammatory balance of bone healing. Because C5a activates the endothelium and enhances cell migration,1,31,32 it may increase the number of inflammatory cells, such as macrophages and polymorphonuclear neutrophils in the fracture hematoma. C5a influences the function of leukocytes by inducing cytokine release as well as the production of proteases and reactive oxygen species.33,34 This was confirmed by Flierl et al.1 in their rat model of blunt chest trauma. An increased number and changed activity of neutrophils could, therefore, enhance and/or prolong the inflammatory phase of fracture healing. This was confirmed by studies reporting improved fracture healing after the depletion of neutrophils35 or disturbed healing by the application of zymosan, which stimulates the generation of reactive oxygen species by leukocytes.36 C5a can prime macrophages to a more pro-inflammatory phenotype, leading to an increased secretion of cytokines in response to a second inflammatory stimulus.34 An increased release of inflammatory cytokines from macrophages has been shown to provoke delayed fracture healing.37 Furthermore, C5a could act as a potent inhibitor of angiogenesis by pushing macrophages towards an angiogenesis-inhibitory phenotype,22 therefore possibly generating negative effects on bone regeneration. C5a might not only influence inflammatory cells but also osteoblast progenitors and osteoblasts as well as osteoclasts. It is a chemotactic factor for mesenchymal stem cells and osteoblasts, suggesting that it may modulate the recruitment of these cells to the site of injury.15,38 It was reported that osteoblast-like osteosarcoma cells (MG-63) expressed functional C5aR and responded to C5a by releasing IL-6.16 C5a appears also to increase osteoclast formation directly by binding to C5aR on osteoclast precursors and indirectly by increasing the expression of receptor activator of nuclear factor-κB (RANKL) and IL-6 in osteoblasts,17 which could in turn stimulate

### Table 2. Number of Bridged Cortices of the Calli Evaluated by μ-Computed Tomography in Two Planes of Rats without (Control) or with Treatment with a C5aR-Antagonist

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of Bridged Cortices</th>
<th>Clinical Fracture Healing Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0  2  0  0  4</td>
<td>Control 3  5</td>
</tr>
<tr>
<td>C5aR-antagonist</td>
<td>0  0  0  1  7</td>
<td>C5aR-antagonist 0  8</td>
</tr>
</tbody>
</table>

![Figure 2. Absolute amounts of osseous tissue (TOT), cartilage tissue (Cg) and fibrous tissue (FT) within the callus of rats without (Ctrl) or with treatment with a C5aR-antagonist.](image-url)
osteoclast formation and activity.\textsuperscript{39} Taken together, systemic C5a could trigger a number of events in inflammatory cells as well as osteoblast and osteoclasts in the early phase of fracture healing, which might lead to a prolonged and/or increased inflammatory phase, and as a consequence to disturbed fracture healing. As outlined before, complement might be essential for regular regeneration processes during all stages of fracture healing. Therefore, it could be speculated that blocking complement during the whole healing period might have negative effects. Currently, further studies are ongoing in our group to prove this hypothesis.

In conclusion, our results demonstrate that the increase of C5a during the posttraumatic systemic inflammation considerably accounts for the deleterious effects of a blunt chest trauma on fracture healing and that immunomodulation by a C5aR-antagonist in the acute posttraumatic phase could abolish this effect, possibly via influencing the function of inflammatory and bone cells contributing to the early phase of fracture healing. Therefore, C5a could possibly represent a target to prevent delayed bone healing in patients with severe trauma.\textsuperscript{4,5}

ACKNOWLEDGMENTS

This study was funded by the German Research Foundation (KFO 200) and by National Institutes of Health grants AI068730 (to J.D.L.). The authors appreciate the technical assistance of Uwe Wolfram, Ursula Maile, and Marion Tomo. Each author in this manuscript has not and will not receive benefits in any form from a commercial party related directly or indirectly to the content of this manuscript.

REFERENCES